Sino Biological and BioGeometry Expand Partnership to Revolutionize Protein Design with AI

Sino Biological, a leader in recombinant protein production, is expanding its strategic partnership with BioGeometry, a pioneer in digital biology. This enhanced collaboration merges Sino Biological’s expertise in protein expression and wet-lab capabilities with BioGeometry’s cutting-edge generative AI platform for protein design and optimization. The partnership aims to unlock new market opportunities and significantly boost the efficiency of protein research and development.

Sino Biological is renowned for its innovation in biomanufacturing, combining advanced protein and antibody research with BioGeometry’s breakthroughs in AI. BioGeometry, known for its GeoFlow model, excels in protein structure prediction and design. The integration of BioGeometry’s AI tools with Sino Biological’s wet-lab services promises to accelerate protein discovery and optimize R&D processes for researchers and pharmaceutical companies.

Generative AI, particularly through models like AlphaFold3 and GeoFlow, is revolutionizing biomanufacturing by enhancing the accuracy and speed of protein design. BioGeometry’s GeoFlow model, introduced in June, rivals AlphaFold3 in predicting antigen-antibody complexes, streamlining protein research with fewer experiments. This technology, available for non-commercial use, is integrated into BioGeometry’s GeoBiologics platform to improve protein design efficiency.

The partnership will leverage BioGeometry’s AI-driven platform and Sino Biological’s protein expression expertise to enhance research tools and contract research organization (CRO) services. By combining AI with experimental data, the collaboration aims to accelerate project timelines and drive innovations in biopharmaceuticals, disease treatment, and sustainable development.

Sino Biological, headquartered in Beijing, is a global leader in protein and antibody research, offering a comprehensive CRO service platform. Its extensive product range and high-speed production capabilities make it a top player in life science research. BioGeometry, founded in 2022, is at the forefront of AI4Protein innovation, using its advanced AI models to push the boundaries of protein design and optimization.

Looking forward, Sino Biological and BioGeometry will continue to explore AI applications in protein research, aiming to advance biopharmaceutical R&D and contribute to scientific progress and disease treatment.